Shots: Exscientia to receive ~$50M as up front, ~$125M as milestones and additional clinical, regulatory, and commercial milestones of over $1.2B along with royalties on net sales of any marketed […]readmore
Tags : Immunology
The increasing cases of autoimmune disorders such as rheumatoid arthritis are driving the growth of immunology products in the global market. Multiple companies have been focusing on Oncology, Hematology and […]readmore
Shots: Novimmune to receive $115.86M, out of $518.76M and has already received $402.9M under its exclusive license agreement signed with Sobi in 2018. Sobi to get IP & patent rights, […]readmore
Shots: Avidity to receive $20M upfront, $15M equity investment, $405M as development, regulatory & commercial milestones for each target and royalties on sales. Lilly to get WW rights to develop […]readmore
Shots: This acquisition is expected to increase continued access for Shire in plasma collection network advancing its facilities of supply and manufacturing units Shire will take over Sanaplasma AG’s 14 […]readmore